Skip to content
DataLookout
Menu

NCT07018297

Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date: Aug 2026 to Aug 2028
    • Eligibility criteria expanded, about 11 words
    • Primary completion pushed from Aug 1, 2028 to Sep 1, 2028
    • Publications: details revised at 7 of 7 entries
  2. Notable Primary completion pushed from Aug 1, 2027 to Aug 1, 2028
    • Start date: Feb 2026 to Aug 2026
    • Study completion pushed from Sep 1, 2027 to Sep 1, 2028
    v6
  3. Notable Start date: Dec 2025 to Feb 2026v5
  4. Notable Start date: Sep 15, 2025 to Dec 2025v4
  5. Notable Start date: Aug 1, 2025 to Sep 15, 2025v3
  6. Minor Secondary endpoints: details revised at 1 of 3 entries
    • Study description expanded, about 1 word
    v2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Days alive and out of the hospital
Timeframe: 30-day

Secondary (3)

Change in Quality of Life
Change in N-terminal pro B-type natriuretic peptide
Time-to-event for mortality and readmission

Arms and interventions

Early Discharge with Subcutaneous FurosemideExperimental

The practice group randomized to early discharge with subcutaneous furosemide home infusion will begin initiation of subcutaneous furosemide (LASIX-ONYU) with a SQIN-Infusor device prior to discharge from the hospital. Dosing will be based on pre-admission oral furosemide requirements. Those with a home dose of ≤80mg/day oral furosemide will receive 80mg subcutaneous once daily at home and those with \>80mg/day oral furosemide will receive 80mg subcutaneous twice daily at home.

Usual CareNo intervention

Usual inpatient care with IV furosemide. Discharge timing determined by treating physician per standard practice.

Combination products: Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor

Sites

2 sites in 1 country